Abstract:Objectives: To summarize the efficacy of midodrine as an adjunctive therapy in critically ill patients. Safety of midodrine was assessed as a secondary outcome. Data sources: We performed a systematic review and meta-analysis using a peer-reviewed search strategy combining the themes of vasopressor-dependent shock, critical care, and midodrine and including MEDLINE, Ovid Embase, CINAHL, and Cochrane library databases until September 14, 2023. Study selection: We included studies if they: 1) included patients with vasopressor-dependent shock, 2) were performed in the ICU, 3) evaluated oral midodrine therapy compared with placebo or usual care, and 4) evaluated one of the outcomes of interest. Data extraction: We extracted data independently in duplicate using standardized data abstraction forms, which included the following specific variables: patient characteristics, age, sex, type of ICU, etiology of shock, number of patients, study inclusion and exclusion criteria, and geographical location. We also captured the type, dose, and duration of IV vasopressors, any cointervention used, and outcome data. Data synthesis: We identified seven randomized controlled trials (six included in the pooled analysis) and ten observational studies (four included in the pooled analysis) that met eligibility criteria. Adjunctive midodrine may decrease ICU length of stay (LOS) and there is low certainty of effect on hospital LOS. Midodrine may decrease IV vasopressor support duration, ICU mortality, and hospital mortality. Pooled observational data was based on very low certainty data for all outcomes of interest. The trial sequential analysis-informed required sample size was not met for ICU LOS or IV vasopressor duration and this contributed to Grading of Recommendations, Assessment, Development, and Evaluations assessments of imprecision for both outcomes. Conclusions: Adjunctive midodrine may decrease ICU LOS, duration of IV vasopressor therapy, and mortality in critically ill patients. However, required sample sizes was not met to determine our outcomes of interest. Midodrine may increase risk of bradycardia. While midodrine may provide benefit for patient-centered outcomes, due to increased risk of adverse events, further large-scale studies are needed to inform and guide its routine use in the ICU.

Evaluation of Midodrine Utilization in Patients with Cancer and Heart Failure

Safety of midodrine in patients with heart failure with reduced ejection fraction: a retrospective cohort study

Outcomes with inpatient use of midodrine in patients with heart failure and kidney failure on maintenance dialysis

Potential harm of midodrine in renal failure patients with concomitant heart failure with reduced ejection fraction

Effect of midodrine on HVPG in advanced chronic liver disease and acute‐on‐chronic liver failure—A pilot study

Oral midodrine for prophylaxis against post-spinal anesthesia hypotension during hip arthroplasty in elderly population: a randomized controlled trial

Adjunctive Midodrine Therapy for Vasopressor-Dependent Shock in the ICU: A Systematic Review and Meta-Analysis

Midodrine for the Prevention of Vasovagal Syncope

Midodrine reduces new-onset acute kidney injury and hyponatremia in children with cirrhosis and ascites awaiting liver transplantation: Results from an open-label RCT

Midazolam versus morphine in acute cardiogenic pulmonary edema patients with and without atrial fibrillation: findings from the MIMO trial

Effects of midodrine hydrochloride and L-carnitine on intradialytic hypotension in elderly patients with hemodialysis

Neurohormonal Effects of Intravenous Dopamine in Patients with Acute Heart Failure

Midodrine hydrochloride is effective in the treatment of children with postural orthostatic tachycardia syndrome.

Midregional Pro-Adrenomedullin As a Predictor for Therapeutic Response to Midodrine Hydrochloride in Children with Postural Orthostatic Tachycardia Syndrome.

Safety and Efficacy of Anti-Hypertensive Medications in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis

Difference Between Supine and Upright Blood Pressure Associates to the Efficacy of Midodrine on Postural Orthostatic Tachycardia Syndrome (POTS) in Children

Trimetazidine: A Meta-Analysis Of Randomised Controlled Trials In Heart Failure

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

[Predictive Value of Baseline Plasma Midregional Fragment of Pro-Adrenomedullin Level on Long-Term Outcome of Postural Tachycardia Syndrome Children Treated with Midodrine Hydrochloride].

Effect of add-on naldemedine treatment in patients with cancer and opioid-induced constipation insufficiently responding to magnesium oxide: a pooled, subgroup analysis of two randomized controlled trials

Treatment of Cirrhosis-Associated Hyponatremia with Midodrine and Octreotide